On September 3, 2020 Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, reported that it will host its fourth annual virtual R&D Day for analysts and investors at 8:00 a.m. ET on Thursday, September 17 (Press release, Moderna Therapeutics, SEP 3, 2020, View Source [SID1234564422]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Moderna’s R&D Day will include presentations from Stéphane Bancel, Chief Executive Officer, Tal Zaks, M.D., Ph.D., Chief Medical Officer, Stephen Hoge, M.D., President, clinical team leaders and key opinion leaders with a focus on the Company’s clinical development pipeline.

A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com. A replay of the webcast will be archived on Moderna’s website for one year following the presentation.